Regulation And Legal
Piramal Pharma Denies Material News Behind 10% Rally
Piramal Pharma responds to exchange queries on a news article about its 10% stock price surge.
Company clarifies the news contains no undisclosed material information per SEBI Regulation 30.
Attribute
